| Literature DB >> 32822824 |
Sarabjeet Kour Sudan1, Sachin Kumar Deshmukh1, Teja Poosarla2, Nicolette Paolaungthong Holliday3, Donna Lynn Dyess4, Ajay Pratap Singh5, Seema Singh6.
Abstract
Systemic and organ-confined inflammation has been associated with cancer development and progression. Resistin, initially described as an adipocyte-derived cytokine in mice, is mostly expressed by the macrophages in humans. It has potent pro-inflammatory properties, and its elevated serum levels are detected in cancer patients. Aberrant expression of resistin receptors is also reported in several malignancies and associated with aggressive clinicopathological features. Several lines of evidence demonstrate that resistin, acting through its different receptors, promotes tumor growth, metastasis, and chemoresistance by influencing a variety of cellular phenotypes as well as by modulating the tumor microenvironment. Racially disparate expression of resistin has also attracted much interest, considering prevalent cancer health disparities. This review discusses the aberrant expression of resistin and its receptors, its diverse downstream signaling and impact on tumor growth, metastasis, angiogenesis, and therapy resistance to support its clinical exploitation in biomarker and therapeutic development.Entities:
Keywords: Cancer; Cytokine; Inflammation; Resistin; Tumor microenvironment
Mesh：
Substances：
Year: 2020 PMID： 32822824 PMCID： PMC8117252 DOI： 10.1016/j.bbcan.2020.188419
Source DB: PubMed Journal: Biochim Biophys Acta Rev Cancer ISSN： 0304-419X Impact factor: 10.680